MAY 13, 2026 · JOURNAL ARTICLE
Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis.
Renal Failure
Meta-analysis of 3 RCTs and 8 observational studies shows apixaban and rivaroxaban associated with lower bleeding risk versus warfarin in dialysis patients with AF, but efficacy endpoints show substantial heterogeneity and RCT-only analysis lacked statistical significance; evidence is suggestive but requires dedicated large RCTs.
Reported
Major bleeding risk ratio0.57 (95% CI: 0.51–0.63)
Gastrointestinal bleeding risk ra…0.66 (95% CI: 0.57–0.76)
Intracranial hemorrhage risk ratio0.54 (95% CI: 0.36–0.83)